Palisade Bio Inc (PALI)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$1.54

+0.06 (+4.05%)

Market Cap: $257.92M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

57%(13/23)

Avg Surprise

+18.14%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.06

Range$-0.07 - $-0.05

7 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.060.0%

60d ago$-0.060.0%

30d ago$-0.060.0%

7d ago$-0.060.0%

Current$-0.06

Revenue Consensus

Range$0 - $0

7 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.07

Range$-0.10 - $-0.05

7 analysts

Revenue Consensus

$357140

Range$0 - $500000

7 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.07	$-0.10 - $-0.05	-	-	7	-	-
Sep 30, 2026Sep 26EST	-	$-0.06	$-0.07 - $-0.05	-	-	7	1 5 30d	-
Jun 30, 2026Jun 26 Reported Aug 10, 2026Reported Aug 10	$-0.05	$-0.05	$-0.07 - $-0.04	+0.00%	Beat	7	2 1 30d	+91.4%
Mar 31, 2026Mar 26 Reported May 12, 2026Reported May 12	$-0.05	$-0.04	$-0.06 - $-0.01	-14.50%	Miss	6	0 1 30d	+90.3%
Dec 31, 2025Dec 25 Reported Mar 23, 2026Reported Mar 23	$-0.06	$-0.03	$-0.05 - $-0.01	-97.17%	Miss	6	1 1 30d	+91.9%
Sep 30, 2025Sep 25 Reported Nov 10, 2025Reported Nov 10	$-0.38	$-0.27	$-0.47 - $-0.03	-40.74%	Miss	3	1 1 30d	+83.6%
Jun 30, 2025Jun 25 Reported Aug 11, 2025Reported Aug 11	$-0.58	$-0.56	$-0.62 - $-0.48	-3.57%	Miss	3	No revisions (30d)	+82.5%
Mar 31, 2025Mar 25 Reported May 12, 2025Reported May 12	$-0.47	$-0.81	$-0.84 - $-0.78	+41.98%	Beat	2	No revisions (30d)	+89.8%
Dec 31, 2024Dec 24 Reported Mar 24, 2025Reported Mar 24	$-0.69	N/A	-	+65.27%	Beat	3	0 2 30d	+89.3%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-2.32	$-3.35	$-3.63 - $-3.07	+30.75%	Beat	2	No revisions (30d)	+68.4%
Jun 30, 2024Jun 24 Reported Aug 12, 2024Reported Aug 12	$-3.32	$-2.93	$-3.11 - $-2.75	-13.31%	Miss	2	No revisions (30d)	+58.2%
Mar 31, 2024Mar 24 Reported May 13, 2024Reported May 13	$-4.59	$-3.75	$-3.75 - $-3.75	-22.40%	Miss	1	No revisions (30d)	+43.3%
Dec 31, 2023Dec 23 Reported Mar 26, 2024Reported Mar 26	$-6.45	$-5.17	$-5.19 - $-5.16	-24.76%	Miss	2	No revisions (30d)	-199.7%
Sep 30, 2023Sep 23 Reported Nov 9, 2023Reported Nov 9	$-7.35	$-6.15	$-6.19 - $-6.12	-19.51%	Miss	2	No revisions (30d)	+88.0%
Jun 30, 2023Jun 23 Reported Aug 11, 2023Reported Aug 11	$-7.95	$-6.82	$-6.87 - $-6.78	-16.57%	Miss	2	No revisions (30d)	+91.2%
Mar 31, 2023Mar 23 Reported May 12, 2023Reported May 12	$-8.10	$-9.90	$-9.97 - $-9.84	+18.18%	Beat	2	No revisions (30d)	+37.7%
Dec 31, 2022Dec 22 Reported Mar 22, 2023Reported Mar 22	$6.47	$-2.43	$-2.47 - $-2.40	+366.26%	Beat	2	No revisions (30d)	+103.9%
Sep 30, 2022Sep 22 Reported Nov 14, 2022Reported Nov 14	$-61.06	$-67.50	$-67.51 - $-67.49	+9.54%	Beat	2	No revisions (30d)	+67.4%
Jun 30, 2022Jun 22 Reported Aug 15, 2022Reported Aug 15	$-90.00	N/A	-	+58.62%	Beat	1	No revisions (30d)	-2449.6%
Mar 31, 2022Mar 22 Reported May 13, 2022Reported May 13	$-13.00	$-14.00	$-14.01 - $-13.99	+7.14%	Beat	2	No revisions (30d)	-196.1%
Dec 31, 2021Dec 21 Reported Mar 16, 2022Reported Mar 16	$-165.75	$-180.00	$-180.01 - $-180.00	+7.92%	Beat	2	No revisions (30d)	-66200.0%
Sep 30, 2021Sep 21 Reported Nov 15, 2021Reported Nov 15	$-187.27	$-270.00	$-270.00 - $-270.00	+30.64%	Beat	1	No revisions (30d)	-4165.8%
Jun 30, 2021Jun 21 Reported Aug 24, 2021Reported Aug 24	$-3.53	N/A	-	N/A	Beat	-	-	+19.6%
Mar 31, 2021Mar 21 Reported May 14, 2021Reported May 14	$-4.39	N/A	-	N/A	Beat	-	-	+0.0%
Dec 31, 2020Dec 20 Reported Mar 22, 2021Reported Mar 22	$-0.25	N/A	-	N/A	Beat	-	-	+94.3%
Sep 30, 2020Sep 20 Reported Nov 10, 2020Reported Nov 10	$-4.39	N/A	-	N/A	Beat	-	-	+0.0%
Jun 30, 2020Jun 20 Reported Aug 13, 2020Reported Aug 13	$-4.39	N/A	-	N/A	Beat	-	-	+0.0%
Mar 31, 2020Mar 20 Reported May 15, 2020Reported May 15	$-4.39	N/A	-	N/A	Beat	-	-	-1895.5%
Dec 31, 2019Dec 19 Reported Mar 27, 2020Reported Mar 27	$-4.39	N/A	-	N/A	Beat	-	-	-1895.5%
Sep 30, 2019Sep 19 Reported Nov 14, 2019Reported Nov 14	$-4.39	N/A	-	N/A	Beat	-	-	-3558.3%
Jun 30, 2019Jun 19 Reported Aug 14, 2019Reported Aug 14	$-4.39	N/A	-	N/A	Beat	-	-	-448.8%
Mar 31, 2019Mar 19 Reported May 14, 2019Reported May 14	$-0.22	N/A	-	N/A	Beat	-	-	+92.1%
Dec 31, 2018Dec 18 Reported Mar 22, 2019Reported Mar 22	$-0.22	N/A	-	N/A	Beat	0	No revisions (30d)	-22.2%
Sep 30, 2018Sep 18 Reported Nov 14, 2018Reported Nov 14	$-0.12	N/A	-	N/A	Beat	-	-	+33.3%
Jun 30, 2018Jun 18 Reported Aug 13, 2018Reported Aug 13	$-0.80	N/A	-	N/A	Beat	-	-	+100.0%
Mar 31, 2018Mar 18 Reported Apr 2, 2018Reported Apr 2	$-2.80	N/A	-	N/A	Beat	-	-	+99.9%
Dec 31, 2017Dec 17 Reported Mar 22, 2018Reported Mar 22	$-0.18	$0.00	$0.00 - $0.00	N/A	Miss	0	No revisions (30d)	+100.0%
Sep 30, 2017Sep 17 Reported Nov 8, 2017Reported Nov 8	$-0.18	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	-
Jun 30, 2017Jun 17 Reported Aug 8, 2017Reported Aug 8	$-2160.00	N/A	-	+50.68%	Beat	-	-	-
Mar 31, 2017Mar 17 Reported May 10, 2017Reported May 10	$-2580.00	$-3120.00	-	+17.31%	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Mar 23, 2017Reported Mar 23	$-4200.00	$-3120.00	-	-34.62%	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-2.90	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	-2340.00%
ROE	-51.40%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	24.26x	Quick Ratio	24.26x
Trading Statistics
Beta	1.62	Avg Volume	3.59M
52-Week High	$2.86	52-Week Low	$1.32

Technical Indicators Dashboard

Moving Averages

SMA 10$1.49

SMA 20$1.51

SMA 50$1.83

SMA 200$1.89

EMA 10$1.51

EMA 20$1.57

EMA 50$1.73

EMA 200$1.79

MACD

Line: -0.09Signal: -0.12Hist: 0.02

ADX

ADX: 31.9+DI: 18.7-DI: 28.3

Aroon & PSAR

Aroon Up8.0

Aroon Down56.0

PSAR$1.36

Bollinger Bands

Upper Band$1.69

Lower Band$1.34

%B Position2314%(Upper)

Band Width0.58

RSI (14-Day)

Neutral

45.2

Momentum Oscillators

Stoch %K56.5

Stoch %D57.0

Williams %R-29.0

ROC (10d)7.7%

Momentum0.11

CCI (20d)12.3

MFI (14d)36.1

Volatility Measures

ATR (14d)$0.11(7.1%)

StdDev (20d)0.09

Hist Vol74.1%(High)

Volume Flow

VWAP$1.53

OBV141.0M

AD Line-160.6M

CMF (20d)-0.040

Volume Metrics

Avg Vol (20d)3.3M

Vol Ratio0.6x

VWMA (20d)$1.52

Pivot Points

R3$1.66

R2$1.59

R1$1.53

Pivot Point$1.46

S1$1.40

S2$1.33

S3$1.27

Advanced Oscillators

TSI-21.22

Ultimate Osc55.7

KST-218.46

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$500,000	$0	$0	$0	$0	$0	$4,000	$0	$0	$0	$-250,000	$0
Cost of Revenue	$0	$0	N/A	$0	$0	$0	$2,000	$0	$0	$0	$54,000	$0
Gross Profit	$500,000	$0	N/A	$0	$0	$0	$2,000	$0	$0	$0	$-304,000	$0

Operating Expenses	$12.20M	$10.75M	$9.98M	$2.92M	$2.84M	$2.31M	$3.38M	$3.59M	$4.21M	$3.67M	$3.15M	$3.78M
R&D	$7.40M	$6.40M	$6.17M	$1.39M	$1.68M	$950,000	$2.08M	$2.14M	$2.63M	$2.21M	$1.37M	$2.10M
SG&A	$4.80M	$4.35M	$3.81M	$1.53M	$1.17M	$1.36M	$1.30M	$1.46M	$1.58M	$1.46M	$1.56M	$1.67M
Operating Income	$-11,698,000	$-10,748,000	$-9,981,000	$-2,922,000	$-2,843,000	$-2,310,000	$-3,382,000	$-3,593,000	$-4,211,000	$-3,673,000	$-3,154,000	$-3,778,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$2,000	$5,000	$0	$0	$3,000	$6,000	$2,000	$1,000	$4,000	$8,000
Income Before Tax	$-10,574,000	$-9,600,000	$-8,899,000	$-2,868,000	$-2,782,000	$-2,229,000	$-3,344,000	$-3,487,000	$-4,080,000	$-3,527,000	$-2,971,000	$-3,596,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-10,574,000	$-9,600,000	$-8,899,000	$-2,868,000	$-2,784,000	$-2,230,000	$-3,344,000	$-3,487,000	$-4,080,000	$-3,527,000	$-2,971,000	$-3,596,000

EBITDA	$-10,574,000	$-9,599,000	$-8,897,000	$-2,862,000	$-2,781,000	$-2,228,000	$-3,341,000	$-3,480,000	$-4,077,000	$-3,525,000	$-2,967,000	$-3,587,000
EBIT	$-10,574,000	$-9,599,000	$-8,897,000	$-2,863,000	$-2,782,000	$-2,229,000	$-3,341,000	$-3,481,000	$-4,078,000	$-3,526,000	$-2,967,000	$-3,588,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about PALI

News

H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)

H.C. Wainwright reiterated a Buy rating and a $7.00 price target for Palisade Bio Inc. (PALI). Analyst Mitchell S. Kapoor cited positive Phase 1b data for PALI-2108 in fibrostenotic Crohn’s disease...

StreetInsider•Oct 13, 2026 6:42 PM ET10/13/26•Bullish

HC Wainwright & Co. reiterates Buy rating on Palisade Bio, $7 price target

HC Wainwright & Co. has reiterated its Buy rating on Palisade Bio (PALI) with a price target of $7.00, representing a potential upside of 340.3% from its October 12 close. This positive outlook is based on promising...

TradingView•Oct 13, 2026 6:39 AM ET10/13/26•Bullish

H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)

H.C. Wainwright analyst Mitchell S. Kapoor reaffirmed a Buy rating and a $7.00 price target for Palisade Bio Inc. (PALI). This reiteration follows new data presented at the American College of Gastroenterology (ACG)...

StreetInsider•Oct 13, 2026 6:39 AM ET10/13/26•Bullish

Palisade Bio presents clinical data on ulcerative colitis drug

Palisade Bio Inc. announced positive clinical data for PALI-2108, its investigational oral PDE4 inhibitor prodrug for ulcerative colitis and Crohn’s disease...

Investing.com•Oct 12, 2026 8:42 AM ET10/12/26•Somewhat-Bullish

A Crohn’s gut-exam score fell an average 47.5% in five people after 14 days. The study had no placebo group.

Palisade Bio (Nasdaq: PALI) presented new clinical data at ACG 2026 for its investigational oral therapy PALI-2108 for ulcerative colitis and Crohn's disease...

Stock Titan•Oct 12, 2026 8:10 AM ET10/12/26•Bullish

PALI Valuation and Fair Value

P/E: -2.9x
P/B: 2.7x

See GNG's fair value

PALI Profitability: Margins, ROIC and FCF

Operating margin: -2340.0%
Net margin: 0.0%
ROE: -51.4%
FCF margin: -3638.0%

PALI Competitors

Company	Ticker
Standard Biotools Inc	LAB
Prelude Therapeutics Inc	PRLD
Nautilus Biotechnology Inc	NAUT
EyePoint, Inc	EYPT
Treace Medical Concepts Inc	TMCI
OraSure Technologies Inc	OSUR
InfuSystems Holdings Inc	INFU
Vanda Pharmaceuticals Inc	VNDA

Sector: Healthcare

PALI Analyst Ratings

Consensus: Buy
Analysts: 9
Strong Buy: 2
Buy: 7
Hold: 0
Sell: 0
Strong Sell: 0

PALI Bull Case vs Bear Case

Bull case

100.0% of PALI's analyst ratings are Buy or Strong Buy.

Bear case

PALI beat EPS estimates in 37.5% of its last 8 reported quarters.

PALI Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -2.2%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.06
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 1 up, 5 down

Frequently Asked Questions About PALI

Does PALI pay dividends?

Palisade Bio Inc (PALI) does not currently pay a regular dividend.

What is PALI's market cap?

Palisade Bio Inc (PALI) has a market capitalization of $257.92M with a current stock price of $1.54.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In

Earnings

Performance (10Y)

Upcoming Estimates

Key Metrics

Technical Indicators Dashboard

Moving Averages

MACD

ADX

Aroon & PSAR

Bollinger Bands

RSI (14-Day)

Momentum Oscillators

Volatility Measures

Volume Flow

Volume Metrics

Pivot Points

Advanced Oscillators

Financial Data

Related GNG Research

News

H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)

HC Wainwright & Co. reiterates Buy rating on Palisade Bio, $7 price target

H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)

Palisade Bio presents clinical data on ulcerative colitis drug

A Crohn’s gut-exam score fell an average 47.5% in five people after 14 days. The study had no placebo group.

PALI Valuation and Fair Value

PALI Profitability: Margins, ROIC and FCF

PALI Competitors

PALI Analyst Ratings

PALI Bull Case vs Bear Case

Bull case

Bear case

PALI Earnings: Beat Rate and Next Report

Frequently Asked Questions About PALI

Related stocks

Get full access to GNG Research